Kiniksa Pharmaceuticals (NASDAQ:KNSA) Releases Earnings Results, Beats Estimates By $0.03 EPS

Kiniksa Pharmaceuticals (NASDAQ:KNSA) released its earnings results on Tuesday. The company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.03, Briefing.com reports. Kiniksa Pharmaceuticals had a negative net margin of 3.10% and a negative return on equity of 7.83%. The company had revenue of $108.30 million for the quarter, compared to analysts’ expectations of $90.60 million. During the same quarter in the previous year, the company earned ($0.02) EPS. Kiniksa Pharmaceuticals’s revenue for the quarter was up 51.5% on a year-over-year basis.

Kiniksa Pharmaceuticals Price Performance

Shares of Kiniksa Pharmaceuticals stock traded up $0.71 during trading hours on Thursday, reaching $25.91. The company’s stock had a trading volume of 869,632 shares, compared to its average volume of 429,366. The firm has a 50 day moving average price of $19.72 and a 200-day moving average price of $19.37. Kiniksa Pharmaceuticals has a one year low of $14.12 and a one year high of $27.88. The stock has a market cap of $1.84 billion, a P/E ratio of 244.73 and a beta of 0.38.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the stock. Wedbush lifted their price target on shares of Kiniksa Pharmaceuticals from $30.00 to $34.00 and gave the company an “outperform” rating in a report on Tuesday. Wells Fargo & Company assumed coverage on shares of Kiniksa Pharmaceuticals in a report on Friday, May 3rd. They issued an “overweight” rating and a $34.00 price target on the stock. JPMorgan Chase & Co. lifted their price target on shares of Kiniksa Pharmaceuticals from $26.00 to $30.00 and gave the company an “overweight” rating in a report on Wednesday, May 1st. Finally, Evercore ISI lifted their price target on shares of Kiniksa Pharmaceuticals from $25.00 to $30.00 and gave the company an “outperform” rating in a report on Wednesday, April 24th. Four research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Kiniksa Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $32.00.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.